The Healthcare Data

Quince Announces Phase 3 Results for A-T Therapy eDSP

Quince

vQuince Therapeutics Reports Topline Results from Phase 3 NEAT Trial of eDSP in Ataxia-Telangiectasia Quince Therapeutics a late-stage biotechnology company focused on developing therapies for rare diseases by leveraging the biology of a patient’s own cells, has announced topline results…